Role of botulinum toxin in the treatment of cervical dystonia

Neurologic Clinics

Volumn 26, Issue SUPPL.1, 2008, Pages 43-53

  Molho, Eric ^a,c   Jankovic, Joseph ^b,c   Lew, Mark ^b,c  

^a ALBANY MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCLE RELAXANT AGENT; PROSIGNE; PURTOX;

ARTICLE; BLOOD PRESSURE; BLURRED VISION; CERVICAL DYSTONIA; CLINICAL TRIAL; CONSTIPATION; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DYSPHAGIA; DYSTONIA; ELECTROMYOGRAPHY; FLU LIKE SYNDROME; HEART RATE; HUMAN; INJECTION SITE PAIN; MUSCLE WEAKNESS; PAIN ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; TORTICOLLIS;

EID: 46049089079     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(08)80004-7     Document Type: Article

References (62)

1. Ceballos-Baumann A. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2248 Suppl 1 (2001) 14-20
2. Chan J., Brin M., and Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6 (1991) 119-126
3. Jankovic J., Leder S., Warner D., and Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 41 (1991) 1088-1091
4. Tintner R., and Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep 1 (2001) 337-345
5. Claypool D., Duane D., Ilstrup D., and Melton III L. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord 10 (1995) 608-614
6. Castelon K., Trender-Gerhard I., Kamm C., et al. Service-based survey of dystonia in Munich. Neuroepidemiology 21 (2002) 202-206
7. Jankovic J., Tsui J., and Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the general population. Parkinsonism Relat Disord 13 (2007) 411-416
8. Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord 19 Suppl 8 (2004) 109-115
9. Tintner R., and Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother 2 (2001) 1985-1994
10. Costa J., Espirito-SSanto C., Borges A., et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 1 (2005) CD003633
11. Aoki K. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 443 SSuppl 1 (2003) S9-S15
12. Aoki K., and Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8 Suppl 5 (2001) 21-29
13. Houser M., Sheean G., and Lees A. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. J Neurol Neurosurg Psychiatry 64 (1998) 577-580
14. Eleopra R., Tugnoli V., Quatrale R., et al. Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F. Neurotox Res 9 (2006) 127-131
15. Blasi J., Chapman E., Link E., et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365 (1993) 160-163
16. Schiavo G., Rossetto O., Catsicas S., et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 268 (1993) 23784-23787
17. Lew M. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 18 SSuppl 6 (2002) S142-S146
18. Aoki K. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 (2005) 785-793
19. Voller B., Sycha T., Gustorff B., et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61 (2003) 940-944
20. Comella C., and Thompson P. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol 13 Suppl 1 (2006) 16-20
21. Dauer W., Burke R., Greene P., and Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 121 (1998) 547-560
22. Kessler K., Skutta M., Benecke R., and For the German Dystonia Study Group. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 246 (1999) 265-274
23. Hsiung G., Das S., Ranaway R., et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 117 (2002) 1288-1293
24. Mejia N., Vuong K., and Jankovic J. Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 20 (2005) 592-597
25. ®) for cervical dystonia. Adv Ther 22 (2005) 49-55
26. Foster K., Bigalke H., and Aoki K. Botulinum neurotoxin-from laboratory to bedside. Neurotox Res 9 (2006) 133-140
27. Collins A., and Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology 67 (2006) 1083-1085
28. Berman B., Seeberger L., and Kumar R. Long-tterm safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia. Mov Disord 20 (2005) 233-237
29. Jankovic J., Hunter C., Dolimbek B., et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67 (2006) 2233-2235
30. Jankovic J., Vuong K., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188
31. Brinf MF, Comella CL, Jankovic J, et al, For the CD-0017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord In press.
32. Aoki K. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40 (2002) 923-938
33. Bihari K. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia and hemifacial spasm. Curr Med Res Opin 21 (2005) 433-438
34. Nussgens Z., and Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol 235 (1997) 197-199
35. Odergren T., Hjaltason H., Kaakkola S., et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 64 (1998) 6-12
36. Ranoux D., Gury C., Fondarai J., et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 72 (2002) 459-462
37. Sampaio C., Costa J., and Ferreira J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 19 Suppl 8 (2004) S129-S136
38. Jankovic J., and Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 40 (1990) 277-280
39. Jankovic J., and Schwartz K. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology 43 (1993) 834-836
40. Greene P., Kang U., Fahn S., et al. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 40 (1990) 1213-1218
41. Barbano R. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 24 (2001) 1567-1568
42. Brans J., Lindeboom R., Snoek J., et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 46 (1996) 1066-1072
43. Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 24 (2001) 1568-1570
44. Truong D., Duane D., Jankovic J., et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20 (2005) 783-791
45. Poewe W., Deuschl G., Nebe A., et al., For the German Dystonia Study Group. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64 (1998) 13-17
46. Haussermann P., Marczoch S., Klinger C., et al. Long-tterm follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19 (2004) 303-308
47. Benecke R., Jost W., Kanovsky P., et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 64 (2005) 1949-1951
48. Lew M., Adornato B., Duane D., et al. Botu ulin num to oxin ty ype B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49 (1997) 701-707
49. Brashear A., Lew M., Dykstra D., et al. Safety and efficacy of NeuroBloc (bbotulinum toxin type B) in type A-responsive cervical dystonia. Neurology 53 (1999) 1439-1446
50. Comella C., Jankovic J., Shannon K., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65 (2005) 1423-1429
51. Tintner R., Gross R., Winzer U., et al. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology 65 (2005) 765-777
52. Pappert E., Germanson T., and For The Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord (2007)
53. Brin M., Lew M., Adler C., et al. Safety and efficacy of NeuroBloc (bbotulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 (1999) 1431-1438
54. Factor S., Molho E., Evans S., and Feustel P. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord 20 (2005) 1152-1160
55. Pappert E. Botulinum toxin type B in type A resistant versus responsive subjects with CD. Presented at: 10th International Congress of Parkinson's Disease and Movement Disorders; October 28-November 2, 2006; Kyoto, Japan.
56. Barbano R., Comella C., Fan W., Luergans S., and For the Dystonia Study Group. Utility of adjunctive electro-myography in botulinum toxin injection for cervical dystonia. Mov Disord 20 Suppl 10 (2005) S19
57. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 12 (1997) 100-102
58. Lindeboom R., Brans J., Aramideh M., et al. Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord 13 (1998) 706-712
59. Müller J., Wissel J., Kemmler G., et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 75 (2004) 749-753
60. Skogseid I., Roislien J., Claussen B., and Kerty E. Long-term botulinum toxin treatment increases employment rate in patients with cervical dystonia. Mov Disord 20 (2005) 1604-1619
61. Molho ES, Higgins DS, Celmins DF, et al. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Presented at: 10th International Congress of Parkinson 's Disease and Movement Disorders; October 30, 2006; Kyoto, Japan.
62. Lew MF, Factor S. A 4-year observational study of repeated dosing with botulinum toxin type B in patients with cervical dystonia. Presented at: 58th Annual Meeting of the American Academy of Neurology; April 1-8, 2006; San Diego, Calif.